Read on Twitter
Ticker: $AVDL
Mcap: $460M
Cash: $240M
Stock Price: $7.90
Key investment thesis:
*Company sold all its non-core assets to focus on FT218 , a potential best in class drug candidate with a TAM of $1.7B, in a market currently dominated by $jazz drug Xyrem.
Mcap: $460M
Cash: $240M
Stock Price: $7.90
Key investment thesis:
*Company sold all its non-core assets to focus on FT218 , a potential best in class drug candidate with a TAM of $1.7B, in a market currently dominated by $jazz drug Xyrem.
* FT218 is far more superior than Xyrem in that it is administered once-nightly while Xyrem requires to take two doses in seperate times during the night;
*Superb initial results In light of the recent Phase 3 success show significantly improvement over placebo in all parameters
*Superb initial results In light of the recent Phase 3 success show significantly improvement over placebo in all parameters
, NDA submission should soon follow suit after a successful pre-NDA meeting went according to plan. Managment was coy about NDA in its recent filing plan, this bodes well with the recent insider transactions as it seems management wanted to load up on shares before takeoff.
*Company current cash position allows it to go on its own with the launch however adding a possible deep pocket partner is not out of the question.
The big boys have taken notice of the story, two of the best biotech funds bought/increased their stakes:
The big boys have taken notice of the story, two of the best biotech funds bought/increased their stakes:
RTW INVESTMENTS, LP increased their holding this quarter to 9% of the company while
RA CAPITAL MANAGEMENT, L.P. bought 5% of the company this quarter.
RA CAPITAL MANAGEMENT, L.P. bought 5% of the company this quarter.
Insiders are also pilling in at current prices, just last week a few directors and CEO all purchased additional shares at a price of ~$7.75 for a total of $380,000.
